This invention is directed to a zinc-charged insulin composition that is effective in treating diabetes and lowering and stabilizing blood glucose levels when administered orally. The zinc-charged insulin is acid and enzyme resistant, such that the zinc-charged insulin is capable of surviving the acidic conditions of the stomach. The zinc-charged insulin is capable of being absorbed through the gastrointestinal tract and stored in the liver, such that the zinc-charged insulin is long lasting and pharmacokinetically similar to the insulin normally generated by the body. The invention is further directed to a method of preparing the zinc-charged insulin composition, including: (1) removing any loosely bound surface ions present on an insulin molecule using a chelating agent; and (2) replacing all the loosely bound surface ions with zinc.

A composition includes at least one polymer doped with graphene oxide to induce conductivity in the polymer and at least one agent immobilized at least one of (i) on graphene oxide extending from the surface of the composite material or (ii) within the composite material.

A composition includes at least one polymer doped with graphene oxide to induce conductivity in the polymer and at least one agent immobilized at least one of (i) on graphene oxide extending from the surface of the composite material or (ii) within the composite material.

The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.

The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation.

The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.

The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.

The present disclosure relates to the use of inositol-stabilized arginine silicate complexes (“ASI”) with the addition of free inositol (“I”) to form a composition ASI+I for improving cognitive functioning in humans, particularly video game players.

Lysosomally accumulated substances that release a nitroxy group, or a short chain fatty acid or a product of anaerobic metabolism or a thiol or a sulfide often from an ester or similar labile linkage have anti-inflammatory, anti-cancer and anti-bacterial activity. They are useful in treating infectious, inflammatory and malignant disease.

Prokaryotic cells having a metal-phenolic network coating are disclosed, as are compositions including such cells, methods for their use, and methods for producing such cells.